<DOC>
	<DOCNO>NCT01873508</DOCNO>
	<brief_summary>This single-center , open label , randomize , 3-period cross-over study compare 3 modified-release formulation RO4917523 healthy volunteer . Subjects randomize one six sequence receive single oral dos RO4917523 slow , target fast release modify release ( MR ) capsule along reference intravenous microdose target capsule . A washout period least 21 day occur treatment .</brief_summary>
	<brief_title>A Study Three Modified-Release Formulations RO4917523 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer , 18 55 year age inclusive Healthy status define absence evidence active chronic disease follow detailed medical surgical history complete physical examination Body mass index ( BMI ) 18 30 kg/m2 , inclusive , body weight least 50 kg Females childbearing potential must agree use effective contraception define protocol Nonsmoker least 90 day prior dose Day 1 History presence clinically significant psychiatric condition define protocol Participation clinical study investigational drug within 60 day 5 time halflife ( whichever longer ) precede first administration study drug . Participation 3 drug study within 10 month precede first administration study drug . Clinically significant disease disorder Personal family history long QT syndrome sudden death Any suspicion history alcohol and/or substance abuse dependence last 6 month Subject likely need concomitant medication study ( include dental condition ) , except hormonal contraception HRT Pregnant lactate woman , woman intend become pregnant course study Positive hepatitis B , hepatitis C HIV infection Any confirm significant allergic reaction drug , multiple allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>